Coadministration with a drospirenone progestogen-only pill (POP) has not been studied. CYP3A4 contributes to drospirenone metabolism. Coadministration is predicted to increase drospirenone and clinical monitoring is recommended due to the potential for hyperkalaemia. Drospirenone AUC increased by 58% when a combined oral contraceptive containing drospirenone and ethinylestradiol was coadministered with darunavir/cobicistat. Based on studies with norethisterone used as a progestogen only pill, the contraceptive efficacy of a drospirenone POP is unlikely to be compromised by darunavir/cobicistat.